Research programme: AGE Formation Inhibitors - Synvista

Drug Profile

Research programme: AGE Formation Inhibitors - Synvista

Alternative Names: ALT-946

Latest Information Update: 07 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alteon
  • Developer Synvista Therapeutics
  • Class Acetamides; Antihyperglycaemics; Hydrazines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 24 Jul 2007 Alteon is now called Synvista Therapeutics
  • 22 Nov 2002 A preclinical study has been added to the Diabetes pharmacodynamics section
  • 08 May 2001 Preclinical development for Diabetic nephropathies in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top